论文部分内容阅读
目的:观察雾化吸入普米克令舒治疗婴幼儿喘息的临床疗效,明确早期治疗的重要作用。方法:将93例婴幼儿喘息住院患者随机分为两组,对照组38例在发作期给予雾化吸入β2受体激动剂及M受体阻断剂等;治疗组55例在此基础上加用普米克令舒吸入治疗。分析两组治疗后4周、12周对喘息的临床控制水平。结果 :治疗组治疗4周后喘息完全控制22例(40.0%),部分控制28例(50.9%),未控制5例(9.1%),临床控制50例(90.9%);治疗12周后完全控制45例(81.8%),部分控制9例(16.4%),未控制1例(1.8%),临床控制54例(98.2%)。对照组治疗12周后喘息完全控制5例(13.2%),部分控制12例(31.6%),未控制21例(55.3%),临床控制17例(44.7%),两组比较差异有统计学意义(χ2=39.87,P<0.05)。结论:早期规律吸入糖皮质激素对与提高婴幼儿喘息的控制水平、改善预后十分重要,雾化吸入普米克令舒是治疗婴幼儿喘息的重要措施。
Objective: To observe the clinical effect of inhalation of pulmicort resuscitation infant infantile asthma, clear the important role of early treatment. Methods: Ninety-three infants and young children with wheezing inpatients were randomly divided into two groups, the control group of 38 patients were given nebulization of β2 agonists and M receptor blockers during the attack; the treatment group of 55 patients on this basis Pulmicort resorption therapy. The clinical control of wheezing at 4 weeks and 12 weeks after treatment was analyzed. Results: In the treatment group, 22 patients (40.0%) had wheezing after 4 weeks of treatment, 28 patients (50.9%) under partial control, 5 patients (9.1%) uncontrolled, and 50 patients (90.9%) under clinical control. Control in 45 cases (81.8%), partial control in 9 cases (16.4%), uncontrolled in 1 case (1.8%) and clinical control in 54 cases (98.2%). Twelve weeks after treatment in the control group, 5 cases (13.2%) completely controlled wheezing, partial control in 12 cases (31.6%), uncontrolled in 21 cases (55.3%) and clinical control in 17 cases (44.7%). Significance (χ2 = 39.87, P <0.05). Conclusion: The early regular inhaled glucocorticoid is important to improve the control of infant wheezing and improve the prognosis. Pulmicort respules inhalation is an important measure to treat wheezing in infants.